Market Closed - London S.E. 11:35:07 2024-05-03 am EDT 5-day change 1st Jan Change
4.375 GBX -0.57% Intraday chart for genedrive plc -18.60% -46.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Genedrive enters clinical trial deal in US for MT-RNR1 US approval AN
FTSE 100 up thanks to US economic data AN
Genedrive shares surge as UK's NICE backs test for ischaemic stroke AN
AIM WINNERS & LOSERS: UK NICE backs Genedrive test; Corero renews deal AN
Genedrive's Test Receives Draft Recommendation from UK's NICE MT
EARNINGS AND TRADING: 888 advances US exit; Arrow ups reserve estimate AN
Genedrive plc Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Genedrive down as plans equity raise despite GBP800,000 tax credit AN
Coro seals sale terms, Powerhouse makes good progress AN
Genedrive Seeks Funding for Testing Kit Amid Funding Call Launch of UK-backed Program MT
MoneySupermarket credits Insurance for growth in 2023 AN
Genedrive draws down GBP600,000 on prepayment facility AN
Genedrive Secures Financing Under Equity Prepayment Facility MT
AIM WINNERS & LOSERS: Genedrive shares jump on orders AN
Genedrive shares surge as six countries receive first orders AN
Genedrive Jumps on Receipt of Initial Orders for MT-RNR1 Products MT
Genedrive plc Announces Initial Overseas Orders of Mt-RNR1 Id Kit CI
600 Group disposal and funding talks continue AN
Genedrive plc Announces the Genedrive MT-RNR1 Id Kit Is Now in Routine Use in the Trevor Mann Baby Unit CI
Genedrive shares fall as annual loss widens but focused on investing AN
Earnings Flash (GDR.L) GENEDRIVE Reports FY23 Revenue GBP55,000 MT
Earnings Flash (GDR.L) GENEDRIVE Posts FY23 Loss GBX-5.50 MT
Genedrive plc Reports Earnings Results for the Full Year Ended June 30, 2023 CI
EARNINGS AND TRADING: Southern Energy loss swing; Craven House widens AN
Genedrive to receive GBP1.2 million grant for test kit AN
Chart genedrive plc
More charts
genedrive plc is a United Kingdom-based pharmacogenetic testing company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need pharmacogenetic platform for the diagnosis of genetic variations. The Company’s products include Genedrive MT-RNR1 ID Kit, Genedrive System, and Genedrive CYP2C19 ID Kit. The Company’s flagship product Genedrive MT-RNR1 ID Kit is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. The Genedrive System is a rapid thermocycler and signal detection system, enabling PCR and isothermal based amplification techniques. It is a semi- automated system used for qualitative in vitro molecular diagnostic tests. Its Genedrive CYP2C19 ID Kit Molecular point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.
More about the company

Chiffre d''affaires - Rate of surprise

  1. Stock Market
  2. Equities
  3. EHP Stock
  4. News genedrive plc
  5. Genedrive Jumps on Receipt of Initial Orders for MT-RNR1 Products